{"schema_version":"secwatch.filing_event.v1","accession":"0000318154-23-000061","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2023-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.629680+00:00","generated_at":"2026-06-09T05:04:27.507907+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amgen Q3 revenue $6.9B (+4% YoY); GAAP EPS $3.22 (-19%); Non-GAAP EPS $4.96 (+6%)","bullets":["Total revenues $6.9B (+4% YoY); product sales +5% on 11% volume growth.","GAAP EPS $3.22 (down 19% YoY), includes ~$650M impairment for discontinued AMG 340.","Non-GAAP EPS $4.96 (+6% YoY); non-GAAP operating margin 52.0%.","Free cash flow $2.5B in Q3 vs $2.8B in prior year."],"urls":{"canonical":"https://secwatch.observer/filing/0000318154-23-000061","json":"https://secwatch.observer/filing/0000318154-23-000061.json","markdown":"https://secwatch.observer/filing/0000318154-23-000061.md","text":"https://secwatch.observer/filing/0000318154-23-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000031815423000061/0000318154-23-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000031815423000061/amgn-20231031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T05:04:27.507907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"621e3db8627108c504b12d0db83e8eea0a721277","claim":"AMGEN INC reported third quarter of 2023 results: revenue $6.9 billion.","evidence_excerpt":"of the Horizon acquisition, Amgen has added rare disease medicines that fit well with our broad innovative portfolio.\" Key results include: • Total revenues increased 4% to $6.9 billion in comparison to the third quarter of 2022, resulting from a 5% increase in product sales. Produ ct sales growth was driven by 11% volume growth, partially offset by 3% lower net","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318154/000031815423000061/0000318154-23-000061-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2023"},{"label":"Revenue","value":"$6.9 billion"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}